InspireMD Q4 Revenue Surges 62% to $3.1M, Advances CGuard Prime with FDA Submission
summarizeSummary
InspireMD reported strong fourth-quarter and full-year 2025 financial results, with Q4 revenue increasing 62% year-over-year to $3.1 million and full-year revenue up 28% to $9.0 million. The company also achieved significant gross margin expansion, with Q4 gross profit margin rising to 37.5% from 24.1% in the prior year. These positive financial metrics were driven by robust commercial traction for its CGuard Prime carotid stent system in the U.S. and continued international demand. Operationally, InspireMD completed enrollment in its CGUARDIANS II pivotal trial and submitted a PMA-S to the FDA for CGuard Prime's use in TCAR procedures, which could potentially double its addressable U.S. market. While net loss increased due to investments in its U.S. commercial team and infrastructure, the strong revenue growth and progress on regulatory fronts are material for this small-cap medical device company. Investors will be watching for FDA approval for TCAR indications and further CGuard Prime adoption.
At the time of this announcement, NSPR was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $1.51 to $2.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.